JCI vs STRO · P/E 44, rev $23.60B vs rev $62.0M
Johnson Controls International PLC (JCI) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
JCI currently screens at market cap $87.62B and trailing P/E 43.9. STRO currently screens at market cap $470.8M.
Not investment advice. Open the JCI and STRO stock pages for the full models.
Not investment advice.